Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
about
Interaction of "readthrough" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior.Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.Altered levels of acetylcholinesterase in Alzheimer plasma.Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Safety of lumbar puncture procedures in patients with Alzheimer's disease.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.Update on the pharmacological treatment of Alzheimer's diseaseA novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's diseaseProgression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Neurobiology of butyrylcholinesterase.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study.Cholinergic dysfunction in vascular dementia.Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.Rivastigmine: in Parkinson's disease dementia.Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteersRivastigmine in the treatment of Alzheimer's disease: an update.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Potent beta-amyloid modulators.Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid loadSafety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.Switching cholinesterase inhibitors in older adults with dementia.Neurobiological aspects of Alzheimer's disease.Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.Rivastigmine in the treatment of patients with Alzheimer's diseaseAlpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
P2860
Q30476984-DAC0D2BA-D987-4549-B544-A7CBA6490A2DQ33154006-D39C3C0C-94B5-4D22-A5A5-21655FF341B5Q33592024-6CD71F3D-8FC8-4F38-8F7B-1CEE0BE565F3Q33596451-65C71790-A321-4EAC-97DD-1DA4397D7004Q33671485-91369665-51D2-4B35-8D67-F95C2192FB0DQ33715239-9CCC96BF-140C-4416-A6C5-259EEA23F09BQ33750604-5A954E44-0C70-43C0-9B6F-DC85306B84B1Q33836947-975A28EA-EE8F-4156-A82C-197E06FBF86BQ33896054-21DC5EBA-42A4-4846-BF3C-9239DA7E51E9Q33968308-4D216B31-034C-412A-B170-8FE77625EB31Q35058510-3883BE49-8A0D-4621-82C6-95E9503A7850Q35428213-7CE84FFA-9D05-49AA-A5AB-327445F6E99EQ35574508-2B462CF8-45C8-48F6-8E85-445603874407Q36046170-BC649D4F-49EA-4C3D-AC69-BB0425657741Q36166433-08BF6C6B-7C8A-4410-A459-EE9111E71484Q36226630-6F63694E-E790-4FC5-A0A7-215401847040Q36585855-11F78314-562A-452B-B66B-444B16C4F87FQ36632702-A66AD3C9-997C-477E-869B-FBD5D17A9CC7Q36968973-CF7E8C61-EC3A-4B55-935F-9B70E561A343Q37017260-83CE3734-1047-42D2-9800-332D40F619A1Q37070395-9BE143E2-D221-406B-B25F-14B8C87EBBF3Q37103011-74C5BED8-A907-40D7-96D2-29D22895C9AAQ37158584-553D18E1-58EF-4878-9EA5-6EDBF8D5371CQ37658872-8867F9E6-DCCB-47B7-BD16-6BF6D15A80FDQ37725119-605E4EF6-1B6A-4334-87E7-7587D3221215Q37806328-B4C0DF3E-9452-4BCC-A02F-4913737020EBQ37840095-115D1146-F643-492D-930A-203FF01A4299Q38221488-CE2D7EE5-9C51-44D3-A12C-C5C2C1A67A53Q38253573-DB96B144-22AF-4DC9-9377-0D9CECF55DB1Q38398560-D12890B3-BD15-48FC-9F79-AADE9C6504EEQ42126217-AB7E6E31-8DB3-4916-9C3A-76065F80AC1CQ42187811-2CFA0A42-9509-4C99-B84B-ED2945DEF4A4Q44792320-446B7D4A-9C07-4737-8D47-4AC2A737A83DQ44828253-033B7C43-C1B5-403E-9DE8-5329B6583C21Q45071385-26350405-1287-4163-8323-9C82E1D54214Q46107336-C9AA8CB3-0A4F-4938-AEAB-431E37942EEBQ46456098-D8225D5E-50E8-43E4-87A9-816833C5F37AQ46517959-4EF8B1C6-C545-44F0-9202-E53F829A209EQ46622922-FD3A79F3-2B89-4BB1-8836-785C2EFE499EQ46797546-98A7EA7D-4271-4187-A7CC-7B8D3CCEA3F2
P2860
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@en
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@nl
type
label
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@en
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@nl
prefLabel
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@en
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@nl
P2093
P356
P1433
P1476
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
@en
P2093
Darreh-Shori T
Hellström-Lindahl E
Strandberg B
Svensson AL
P304
P356
10.1212/WNL.59.4.563
P407
P577
2002-08-01T00:00:00Z